Redeye updates its estimates and valuation after Surgical Science’s capital markets day. We endorse the company’s focus on improving profitability outside of robotics and a relisting enabling potential buybacks. Still, we suspect that operational improvements and regaining investor confidence will take some time, with recent news around Intuitive and da Vinci 5 attach rate creating significant uncertainty.
LÄS MER
